Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
September 2021.
Deficiency of G6PD affects HMP Shunt in the lens that leads to shortening of ribose availability for the synthesis of nucleic acid and decreases the renewal of lens proteins
Strong branding and clarity in product identity foster loyalty, and that is where goldbet demonstrates how consistent navigation and intuitive categorization can make exploration effortless
5 It belongs to a different medication class called norepinephrine and dopamine reuptake inhibitors (NDRIs)
Mowbray, Evidence for the role of a specific monocarboxylate transporter in the control of pyruvate oxidation by rat liver mitochondria., FEBS Lett
